IOTA ADNEX模型在中国妇科肿瘤中心评估附件肿块的效能
单中心回顾性诊断准确性研究纳入2017年5月至12月278例附件肿块患者,以术后病理为参考标准,评估IOTA ADNEX模型鉴别良恶性及不同肿瘤类型的效能。含CA 125时鉴别良恶性AUC为0.94(95%CI 0.91-0.97),不含CA 125为0.93(95%CI 0.90-0.96),两者无显著差异(P=0.54);含CA 125时鉴别I期卵巢癌与II-IV期卵巢癌AUC由0.81升至0.92(P=0.04),鉴别II-IV期卵巢癌与卵巢转移AUC由0.58升至0.78(P=0.01)。
要点
- ADNEX模型鉴别附件肿块良恶性效能良好,含CA 125时AUC为0.94(95%CI 0.91-0.97)。
- 含CA 125时鉴别良性卵巢肿瘤与II-IV期卵巢癌AUC达0.99(95%CI 0.97-1.00)。
- 鉴别交界性卵巢肿瘤与I期卵巢癌效能较低,AUC为0.61(95%CI 0.43-0.77)。
核心结论
- IOTA ADNEX模型在中国背景下鉴别附件肿块良恶性及不同卵巢肿瘤类型方面表现出良好至优秀效能,作者认为该模型在临床实践中具有较高价值,可辅助附件肿块患者的术前诊断。
研究设计与样本
- 单中心、回顾性诊断准确性研究,基于2017年5月至12月前瞻性采集的超声数据,纳入278例至少有一个附件(卵巢、卵巢旁或输卵管)肿块的患者,以术后组织病理学诊断为参考标准。
诊断标准与关键数值
- 含CA 125时ADNEX模型鉴别良恶性附件肿块的AUC为0.94(95%CI 0.91-0.97),不含CA 125时为0.93(95%CI 0.90-0.96),两者差异无统计学意义(P=0.54)。
- 含CA 125时模型鉴别不同肿瘤类型的AUC范围为0.61至0.99,鉴别良性卵巢肿瘤与II-IV期卵巢癌的AUC为0.99(95%CI 0.97-1.00)。
- 含CA 125时模型鉴别交界性卵巢肿瘤与I期卵巢癌的AUC为0.61(95%CI 0.43-0.77),鉴别II-IV期卵巢癌与卵巢转移的AUC为0.78(95%CI 0.62-0.90)。
- 含CA 125时模型鉴别I期卵巢癌与II-IV期卵巢癌的AUC为0.92,不含CA 125时为0.81(P=0.04);鉴别II-IV期卵巢癌与卵巢转移的AUC含CA 125时为0.78,不含CA 125时为0.58(P=0.01)。
临床应用与阅片要点
- ADNEX模型可用于附件肿块术前良恶性鉴别,含CA 125时鉴别良性卵巢肿瘤与II-IV期卵巢癌效能优秀(AUC 0.99)。
- 模型对交界性卵巢肿瘤与I期卵巢癌、II-IV期卵巢癌与卵巢转移的鉴别效能较低(AUC分别为0.61和0.78),阅片报告时需注意。
- 含CA 125可提升模型鉴别I期与II-IV期卵巢癌及II-IV期卵巢癌与卵巢转移的效能(AUC分别由0.81升至0.92、由0.58升至0.78)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: To evaluate the diagnostic accuracy of the International Ovarian Tumor Analysis (IOTA) Assessment of Different NEoplasias in the adneXa (ADNEX) model in the preoperative diagnosis of adnexal masses using data from a gynecological oncology center in China.
METHODS: This was a single-center, retrospective diagnostic accuracy study based on ultrasound data collected prospectively, between May and December 2017, from 278 patients with at least one adnexal (ovarian, paraovarian or tubal) mass. Clinical and pathologic information, serum CA 125 level and ultrasonographic findings were collected. All patients underwent surgery and the histopathological diagnosis was used as reference standard. The final diagnosis was classified into five tumor types according to the ADNEX model: benign ovarian tumor, borderline ovarian tumor (BOT), Stage-I ovarian cancer (OC), Stages-II-IV OC and ovarian metastasis. Receiver-operating characteristics (ROC) curve analysis was used to evaluate the diagnostic accuracy of the ADNEX model, with and without inclusion of CA 125 level in the model.
RESULTS: Of the 278 women included, 203 (73.0%) had a benign ovarian tumor and 75 (27.0%) had a malignant ovarian tumor, including 18 (6.5%) with BOT, 17 (6.1%) with Stage-I OC, 32 (11.5%) with Stages-II-IV OC and eight (2.9%) with ovarian metastasis. The performance of the IOTA ADNEX model was good for discriminating between benign and malignant tumors, with an area under the ROC curve (AUC) of 0.94 (95% CI, 0.91-0.97) when CA 125 was included in the model and AUC of 0.93 (95% CI, 0.90-0.96) without CA 125. The AUC values of the model including CA 125 ranged between 0.61 and 0.99 for distinguishing between the different types of tumor, and it showed excellent performance in discriminating between a benign ovarian tumor and Stages-II-IV OC, with an AUC of 0.99 (95% CI, 0.97-1.00). The performance of the model was less effective at distinguishing between BOT and Stage-I OC and between Stages-II-IV OC and ovarian metastasis, with AUC values of 0.61 (95% CI, 0.43-0.77) and 0.78 (95% CI, 0.62-0.90), respectively. Although inclusion of CA 125 did not alter the performance of the ADNEX model in discriminating between benign and malignant lesions (AUC of 0.94 and 0.93 with and without CA 125 level, respectively; P = 0.54), the inclusion of CA 125 in the model improved its performance in discriminating between Stage-I OC and Stages-II-IV OC (AUC increased from 0.81 to 0.92; P = 0.04) and between Stages-II-IV OC and metastatic cancer (AUC increased from 0.58 to 0.78; P = 0.01).
CONCLUSIONS: The IOTA ADNEX model showed good to excellent performance in distinguishing between benign and malignant adnexal masses and between the different types of ovarian tumor in a Chinese setting. Based on our findings, the ADNEX model has high value in clinical practice and can aid in the preoperative diagnosis of patients with an adnexal mass. Copyright © 2019 ISUOG. Published by John Wiley & Sons Ltd.
引用
- Chen H, Qian L, Jiang M, et al. Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China. Ultrasound Obstet Gynecol. 2019. PMID: 31152572. doi:10.1002/uog.20363
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。